Pharmacyclics, Inc.
http://www.pharmacyclics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmacyclics, Inc.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
The Medtech 100 Ranking: A Successful Year But Industry Must Tread Carefully In 2023
Medtech Insight’s just-published ranking of the leading global medtechs based on revenues reported for fiscal 2021 reveals a picture of an industry overwhelmingly in growth, despite – or in some cases because of – the persistent effects of the pandemic.
As Magrolimab AML Studies Chug Along, The Question Becomes How To Combine It
With an FDA hold lifted and enrollment moving quickly, physicians are looking at how to combine magrolimab with other treatments in patients with TP53-mutated AML.
Finance Watch: No New IPOs, But Two Firms Take The SPAC Route
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice